BioCentury | Apr 5, 2019
Product Development

Reaching addiction patients where they’re at

Coming at the opioid crisis from two different angles, NIH’s National Institute on Drug Abuse and Alkermes plc have concluded that ending the epidemic will mean developing ways of getting medication to patients who fall...
BioCentury | Apr 28, 2017
Emerging Company Profile

Cutting cravings

The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from Gilead Sciences Inc. Newco Amygdala Neurosciences Inc. aims to develop ANS-6673 to treat substance abuse disorders currently...
BC Week In Review | Feb 17, 2017
Company News

Gilead, Amygdala deal

Amygdala acquired GS-6637 from Gilead. Gilead received an equity stake and is eligible for undisclosed milestones and royalties. Amygdala expects to begin two or three Phase II trials this year of GS-6637 in alcohol and...
BC Extra | Feb 16, 2017
Company News

Amygdala acquires addiction candidate from Gilead

Amygdala Neurosciences Inc. (Palo Alto, Calif.) said it acquired GS-6637 from Gilead Sciences Inc. (NASDAQ:GILD). The company expects to begin clinical trials this year of the candidate to treat cocaine and alcohol use disorders. GS-6637...
Items per page:
1 - 4 of 4